Clinical-stage healthcare firms GenFleet Therapeutics and ABM Therapeutics have raked in $79 million and $30 million, respectively.
Genfleet nets $79m in Series C round
Clinical-stage biotechnology firm GenFleet Therapeutics has garnered nearly 500 million yuan ($79 million) in its Series C round of financing, per a company statement on Tuesday.